Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prospective Study of Eslicarbazepine in Adults With Focal-Onset Seizures
Sponsor: King Edward Medical University
Summary
This prospective multicenter observational study will evaluate the effectiveness, safety, tolerability, and impact on quality of life of eslicarbazepine in adults with focal-onset seizures in routine clinical practice. Participants will include newly diagnosed patients and patients previously treated with carbamazepine or oxcarbazepine who have inadequate seizure control or intolerable adverse effects. Treatment with eslicarbazepine will be initiated or changed at the discretion of the treating physician in accordance with routine clinical practice. Participants will be followed for 3 months.
Official title: A Prospective, Real-World Evidence, Multicenter Study to Evaluate the Efficacy and Safety of Eslicarbazepine in Managing Epilepsy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1500
Start Date
2025-12-02
Completion Date
2026-12-31
Last Updated
2026-09-09
Healthy Volunteers
No
Conditions
Interventions
Eslicarbazepine acetate
Eslicarbazepine acetate administered orally once daily as prescribed by the treating physician in routine clinical practice. Newly diagnosed patients will typically initiate treatment at 400 mg/day and increase to 800 mg/day after one week. Patients switching from carbamazepine or oxcarbazepine may initiate treatment at 400-600 mg/day according to clinical judgment. Dose adjustments, including increases up to 1600 mg/day when clinically indicated and tolerated, will be determined by the treating physician.
Locations (1)
Mayo Hospital Lahore
Lahore, Punjab Province, Pakistan